Pfizer Will Not Launch EU Adalimumab

Despite Expected Imminent Approval For Amsparity Biosimilar To Humira

 
• By David Wallace
  
Bad weather
Pfizer cited ‘unfavorable conditions’ as the reason for its decision • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products